Tourmaline Bio Statistics
Share Statistics
Tourmaline Bio has 25.64M shares outstanding. The number of shares has increased by -0.02% in one year.
| Shares Outstanding | 25.64M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 15.60M |
| Failed to Deliver (FTD) Shares | 38 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 1.64M, so 6.41% of the outstanding shares have been sold short.
| Short Interest | 1.64M |
| Short % of Shares Out | 6.41% |
| Short % of Float | 10.94% |
| Short Ratio (days to cover) | 8.65 |
Valuation Ratios
The PE ratio is -2.95 and the forward PE ratio is -7.34.
| PE Ratio | -2.95 |
| Forward PE | -7.34 |
| PS Ratio | 0 |
| Forward PS | 47.8 |
| PB Ratio | 0.61 |
| P/FCF Ratio | -4.42 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Tourmaline Bio Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 41.76, with a Debt / Equity ratio of 0.
| Current Ratio | 41.76 |
| Quick Ratio | 41.76 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.2 |
| Cash Flow / Debt | -67.67 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.21% and return on capital (ROIC) is -22.1%.
| Return on Equity (ROE) | -0.21% |
| Return on Assets (ROA) | -0.2% |
| Return on Capital (ROIC) | -22.1% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -569.24K |
| Employee Count | 74 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -41.9% in the last 52 weeks. The beta is 0, so Tourmaline Bio 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -41.9% |
| 50-Day Moving Average | 23.53 |
| 200-Day Moving Average | 19.39 |
| Relative Strength Index (RSI) | 33.05 |
| Average Volume (20 Days) | 194.80K |
Income Statement
| Revenue | n/a |
| Gross Profit | -33.00K |
| Operating Income | -45.41M |
| Net Income | -42.12M |
| EBITDA | -45.38M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -8.87 |
Balance Sheet
The company has 140.73M in cash and 415.00K in debt, giving a net cash position of 140.31M.
| Cash & Cash Equivalents | 140.73M |
| Total Debt | 415.00K |
| Net Cash | 140.31M |
| Retained Earnings | -62.05M |
| Total Assets | 328.45M |
| Working Capital | 286.50M |
Cash Flow
In the last 12 months, operating cash flow was -28.08M and capital expenditures -56.00K, giving a free cash flow of -28.14M.
| Operating Cash Flow | -28.08M |
| Capital Expenditures | -56.00K |
| Free Cash Flow | -28.14M |
| FCF Per Share | -5.93 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TRML pays an annual dividend of $15.12, which amounts to a dividend yield of 77.66%.
| Dividend Per Share | $15.12 |
| Dividend Yield | 77.66% |
| Dividend Growth (YoY) | 0.01% |
| Payout Ratio | -607.23% |
| Earnings Yield | -47.56% |
| FCF Yield | -5.88% |
Analyst Forecast
The average price target for TRML is $50, which is 168.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $50 |
| Price Target Difference | 168.1% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Oct 20, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Oct 20, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 44.55 |
| Piotroski F-Score | 3 |